-
Execution of Three-S plan driving sequential improvement in operating results and market share gains across U.S. Store Brand OTC and key European brands
-
Infant Formula divestiture expected to simplify portfolio and sharpen focus on higher-return consumer self care categories; strategic review of Oral Care business remains ongoing
-
Updated full-year 2026 outlook to reflect divestiture, more measured retailer inventory positioning, and continued softness in Europe
DUBLIN, Nov. 4, 2026 /PRNewswire / -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of consumer self-care products_,_ today announced financial results from continuing operations for the third quarter ended September 26, 2026.

"Our Three-S plan is delivering continued progress in the areas of the business within our control," said Albert Manzone, Interim President and Chief Executive Officer. "We gained market share again in U.S. store brand OTC and in key European brands. Category trends improved sequentially, which, combined with disciplined cost management, helped offset a difficult consumer backdrop.
"The sale of Infant Formula is an important step in evolving Perrigo into a more focused consumer self-care company. It is expected to enhance our margin profile, materially reduce expected future capital expenditures, and support continued deleveraging and reinvestment in the business. The result will be a simpler Perrigo, better positioned for profitable growth.
"We have adjusted our full-year outlook to reflect the divestiture, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in Europe. Our underlying model, combining scaled brands and store brands in categories people need every day, remains unchanged, and the actions we are taking to simplify Perrigo are positioning us for more consistent and profitable growth over the long term."
Third Quarter Results
| All In**(1)** | Core**(1)** | ||||||||||
| 3Q'26 | 3Q'25 | Change | 3Q'26 | 3Q'25 | Change | ||||||
| Reported Net Sales | $989 | $1,043 | (5.2) % | $908 | $924 | (1.7) % | |||||
| Reported Gross Margin | 32.4 % | 36.1 % | (370)bps | ||||||||
| Reported Operating Margin | 2.3 % | 7.0 % | (460)bps | ||||||||
| Reported Diluted Earnings Per Share ("EPS") | $(0.10) | $0.09 | n/m | ||||||||
| All In | Core | ||||||||||
| 3Q'26 | 3Q'25 | Change | 3Q'26 | 3Q'25 | Change | ||||||
| Organic Net Sales(2) | $994 | $1,013 | (1.9) % | $913 | $924 | (1.1) % | |||||
| Adj. Gross Margin | 36.3 % | 39.9 % | (370)bps | 37.9 % | 39.4 % | (140)bps | |||||
| Adj. Operating Margin | 13.1 % | 16.6 % | (360)bps | 14.3 % | 16.5 % | (210)bps | |||||
| Adj. Diluted EPS | $0.60 | $0.80 | (25.0) % | $0.61 | $0.67 | (9.0) % |
| * Absolute amounts in millions. Data may not add due to rounding. Percentages are based on actuals. |
| (1) As previously announced, the Company now reports results on both an All In and Core Perrigo basis. All In results reflect the entirety of our business, while Core represents our go-forward business and excludes Infant Formula and previously announced divestitures. |
| (2) See attached Appendix for details. Change in net sales on an organic basis excludes the effects of acquisitions, divestitures and exited products, and the impact of currency. |
Net Sales
- Core net sales were $908 million, declining 1.7% year-over-year, while Core organic net sales decreased 1.1%. Results reflected lower consumption in our Self Care segment, which led to more measured retailer inventory positioning ahead of the cough and cold season within the Upper Respiratory and Pain & Sleep categories. Performance was also impacted by lower contract manufacturing volumes. Partially offsetting those factors were continued share gains across U.S. Store Brand OTC and key European brands, supported by innovation and enhanced consumer marketing initiatives. Pricing decreased 0.4% and volume/mix decreased 0.7%.
- All In reported net sales declined 5.2% year-over-year to $989 million. All In results were primarily driven by the same factors as Core net sales in addition to the year-over-year impact of divestitures and lower Infant Formula net sales.
Gross Margin
- Reported All In gross margin was 32.4%, a decrease of 370 basis points.
- Core adjusted gross margin decreased 140 basis points to 37.9% driven by lower net sales volumes and unfavorable mix. These headwinds were partially offset by the net recognition of a recovery of a portion of previously paid tariffs and continued market share gains.
- All In adjusted gross margin decreased 370 basis points to 36.3%, driven by the same factors impacting Core adjusted gross margin in addition to the impact of divestitures and lower Infant Formula gross margin, which included the impact of planned under absorption.
Operating Margin
- Reported operating margin was 2.3%, a decrease of 460 basis points.
- Core adjusted operating margin decreased 210 basis points to 14.3% due to unfavorable gross profit flow through and higher operating expenses, primarily driven by increased advertising and promotional investments and the normalization of variable employee compensation. This decline was partially offset by benefits from the Operational Enhancement Program.
- All In adjusted operating margin decreased 360 basis points to 13.1%, driven by the same factors impacting Core adjusted operating margin as well as the impact of divestitures and Infant Formula.
Other Items
- Reported interest and other expense decreased $9.0 million to $41.2 million.
- Net adjusted interest and other expense increased $0.5 million to $41.2 million.
- The Company's reported effective tax rate was 21.1%. The Company's adjusted effective tax rate decreased to 3.5%, reflecting changes in the jurisdictional mix of earnings.
Diluted EPS
- Reported diluted EPS was $(0.10) compared to $0.09 in the prior year.
- Core adjusted EPS declined $0.06 to $0.61, a 9.0% decrease from the prior year. Results were impacted by a reduction in net sales and operating income, partially offset by a lower effective tax rate, which benefited results by $0.10.
- All In adjusted diluted EPS declined $0.20 to $0.60, a 25.0% decrease from the prior year due to the same factors impacting Core adjusted EPS in addition to the impact of divestitures and Infant Formula. Results also reflected approximately $0.12 of unfavorable EPS impact from planned under absorption within Infant Formula.
Business Segment Results
| 3Q'26 | 3Q'25 | Change | Organic Change | ||||
| Segment net sales: | |||||||
| Self Care | $613 | $633 | (3.2) % | (2.8) % | |||
| Specialty Care | 182 | 191 | (4.6) % | (3.5) % | |||
| Infant Formula | 81 | 89 | (9.6) % | (9.5) % | |||
| Total segment net sales | 876 | 914 | (4.1) % | (3.6) % | |||
| All Other | 113 | 130 | (13.1) % | 14.0 % | |||
| Consolidated net sales | $989 | $1,043 | (5.2) % | (1.9) % |
| 3Q'26 | 3Q'25 | Change | |||
| Segment adjusted operating income: | |||||
| Self Care | $105 | $131 | (19.4) % | ||
| Specialty Care | 32 | 42 | (24.2) % | ||
| Infant Formula | (1) | 15 | n/m | ||
| Total segment adjusted operating income | $137 | $187 | (27.0) % | ||
| All Other | 27 | 23 | 18.4 % | ||
| Unallocated | (34) | (36) | (6.1) % | ||
| Consolidated adjusted operating income | $129 | $173 | (25.5) % |
* Absolute amounts in millions. Amounts may not sum due to rounding. Percentages are based on actuals.
Self Care
Net sales decreased 3.2% compared to the prior year, inclusive of a 0.2% unfavorable impact of currency translation. Results reflected lower consumption, which led to more measured retailer inventory positioning ahead of the cough and cold season within the Upper Respiratory and Pain & Sleep categories. Performance was also impacted by lower contract manufacturing volumes and the unfavorable impact of pricing. These pressures were partly offset by growth in the Healthy Lifestyle category, driven by continued share gains of store brand nicotine replacement products, and the Digestive Health category, supported by higher volumes of store brand laxative products.
Segment adjusted operating income decreased 19.4%, primarily due to unfavorable gross profit flow through driven by unfavorable production variances, unfavorable mix, and higher advertising and promotional investments. These pressures were partially offset by benefits from the Operational Enhancement Program.
Specialty Care
Net sales decreased 4.6% compared to the prior year, inclusive of a 1.1% unfavorable impact of currency translation. Women's Health delivered strong growth, led by solid momentum and share gains for ellaOne_®_ and continued growth from Opill_®. Within the Skin Health category, strong in-season performance from Compeed_® and Jungle Formula_®_ was more than offset by lower sales of store brand and contract manufactured Minoxidil in addition to lower net sales of Mederma_®_.
Segment adjusted operating income decreased 24.2% due to unfavorable production variances, unfavorable mix in Skin Health, and higher advertising and promotional investments across the segment. These pressures were partially offset by benefits from the Operational Enhancement Program.
Infant Formula
Net sales decreased 9.6% compared to the prior year. Growth in store brand infant formula was more than offset by expected lower contract manufacturing volumes, reflecting the shift of certain contract formula shipments that were recorded in the second quarter.
Segment adjusted operating income decreased primarily due to unfavorable gross profit flow through, including planned under absorption, which was partially offset by lower operating expenses.
All Other
Net sales decreased 13.1%, inclusive of a 1.2% unfavorable impact of currency translation, primarily due to the impact of divestitures.
Segment adjusted operating income increased 18.4% due to the net recognition of a recovery of a portion of previously paid tariffs, in addition to improved productivity and lower operating expenses in the Oral Care category. These factors more than offset the impact of divestitures.
Cash Flow and Balance Sheet
- Net cash from operating activities was $96 million in the third quarter.
- Third quarter capital expenditures were $18 million and the Company returned $40 million to shareholders through dividends.
- Cash and cash equivalents as of September 26, 2026 were $437 million while total debt was $3.3 billion.
- Subsequent to quarter-end, the Company announced an agreement to divest its Infant Formula business for total consideration of up to $175 million. The transaction consideration consists of $40 million in upfront cash at closing and up to an additional $135 million contingent on the achievement of net sales milestones through 2030. Net proceeds are expected to be deployed in accordance with Perrigo's capital allocation priorities. The divestiture is expected to simplify our portfolio and sharpen our focus on higher-return consumer self care categories, while enhancing the Company's margin profile. After considering expected carrying value relative to cash proceeds and an estimate of fair value of the contingent milestones, we expect to recognize an impairment loss between $275.0 million and $375.0 million resulting from the measurement as held for sale during the fourth quarter of 2026.
Fiscal 2026 Outlook
Beginning with the fourth quarter and full-year 2026 reporting, the Infant Formula business will be reported as discontinued operations. Accordingly, the Company's All In outlook no longer includes Infant Formula but continues to include other divested businesses. The Company's Core outlook continues to exclude Infant Formula and previously-announced divestitures. For fiscal 2026, the Company has updated its outlook and related assumptions to reflect the Infant Formula divestiture, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in the European consumer environment.
| All In****1 | ExDivestitures | Core****2 | ForeignCurrency | Organic | |||||
| Net Sales Growth YoY | (5.7)% to (4.6)% | ~210 bps | (3.6)% to (2.5)% | (0.2) % | (3.8)% to (2.7)% | ||||
| Adj. Gross Margin | 37.8% to 38.8% | ~(30) bps | 37.5% to 38.5% | ||||||
| Adj. Operating Margin | 14.3% to 15.3% | ~(30) bps | 14.0% to 15.0% | ||||||
| Adj. EPS | $2.25 to $2.45 | ~$(0.10) | $2.15 to $2.35 |
Other assumptions****3
- Net interest expense of approximately $162 million.
- Adjusted effective tax rate of approximately 14.0%.
- Adjusted weighted average shares outstanding of approximately 140 million.
- Net leverage of approximately 4.0 times adjusted EBITDA.
- Cash from operating activities as a percentage of adjusted net income in the low-to-mid-60% range.
| (1) Prior All In guidance included Infant Formula results and reflected net sales growth YoY of (5.5)% to (1.5)%, adjusted gross margin of 36.5% to 37.5%, adjusted operating margin of 12.5% to 13.5%, and adjusted EPS of $2.00 to $2.30. |
| (2) Prior Core guidance excluded Infant Formula results and previously announced divestitures and reflected net sales growth YoY of (3.0)% to 1.0%, adjusted gross margin of 39.0% to 40.0%, adjusted operating margin of 15.0% to 16.0%, and adjusted EPS of $2.25 to $2.55. |
| (3) Prior other assumptions reflected net interest expense of $156M, adjusted effective tax rate of ~18%, adjusted weighted shares outstanding of 139.3M, net leverage at, or slightly lower than, approximately 4.0 times adjusted EBITDA, and cash from operating activities as a percentage of adjusted net income in the mid-60% range. |
Webcast and Conference Call Information
Perrigo previously announced that management will host a call/webcast to discuss its third quarter 2026 financial results beginning at 08:30 A.M. (ET) Wednesday, November 4, 2026. The call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 91025. A taped replay of the call will be available beginning at approximately 12:00 P.M. (ET) Wednesday, November 4, until midnight Wednesday, November 11, 2026. To listen to the replay, dial 888-660-6345, International 646-517-4150, and use access code 91025#.
About Perrigo
Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.






